ASSURE Wearable ECG vs prolaio eVO2peak Module
AI Verdict
Choose ASSURE Wearable ECG if…
Choose ASSURE Wearable ECG if you require a dedicated, continuous, and real-time ECG monitoring solution for at-risk cardiac patients. This tool is ideal for direct patient management, providing immediate alerts and detailed physiologic trend data for clinician review. It's best suited for scenarios where direct, always-on cardiac rhythm surveillance is paramount.
View ASSURE Wearable ECG →Choose prolaio eVO2peak Module if…
Choose prolaio eVO2peak Module if your primary need is to estimate peak oxygen consumption (eVO2peak) for cardiovascular research, risk stratification, or as an adjunctive aid in clinical evaluation. This software-only solution is perfect for leveraging data from existing FDA-cleared third-party wearable sensors to derive a crucial physiological metric. It's particularly useful for retrospective analysis or when integrating eVO2peak estimation into broader patient data workflows.
View prolaio eVO2peak Module →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | ASSURE Wearable ECG | prolaio eVO2peak Module |
|---|---|---|
| Pricing | Contact for pricing. | Contact for pricing |
| Deployment | Wearable device, mobile application, and cloud-based remote patient data platform. | Cloud-based (software-only, processes remote sensor data) |
| BAA Available | Yes AI-estimated | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
ASSURE Wearable ECGKestra Medical Technologies explicitly prioritizes comfort, safety, and usability in the design of the ASSURE system, with features like the SensorFit Garment and a patient app. High patient compliance, with a median wear time of over 23 hours per day, further supports its strong usability in a real-world setting. Tool B, being software-only and reliant on third-party sensors, does not offer the same integrated and patient-centric usability features.
Clinical Value
ASSURE Wearable ECGWhile both offer significant clinical value, Tool A provides continuous, real-time ECG monitoring with advanced artifact reduction and alert-based notifications, which are critical for immediate management of 'at-risk cardiac patients' and detection of acute cardiac events. Its clinical studies demonstrate high effectiveness in arrhythmia conversion and a low inappropriate shock rate for the related WCD system, directly impacting patient safety and outcomes. Tool B offers a valuable prognostic metric (eVO2peak) but as an 'adjunctive aid' and not for active patient monitoring or as an alarm device.
Pricing & Value
TieBoth tools explicitly state 'contact for pricing' and do not provide any public details on their cost structure or specific value-based outcomes. Without this information, it is impossible to conduct a comparative assessment of their pricing and overall value.
Enterprise Readiness
ASSURE Wearable ECGBoth tools meet fundamental enterprise readiness requirements with FDA clearance, HIPAA compliance, and BAA availability. However, Tool A offers a more comprehensive and integrated ecosystem, including its own wearable device, mobile application, and a dedicated cloud-based remote patient data platform (Kestra CareStation) for clinician review. This integrated approach suggests a more streamlined and managed solution for healthcare enterprises.
Innovation
prolaio eVO2peak ModuleWhile Tool A demonstrates innovation in wearable hardware and advanced signal processing for ECG monitoring, Tool B's core innovation lies in its application of a locked deep-learning model to accurately estimate peak oxygen consumption (eVO2peak) from diverse, real-world patient data collected by third-party sensors. This AI-driven approach to derive a complex physiological metric from readily available data represents a significant advancement in clinical intelligence and predictive analytics.
Support & Docs
ASSURE Wearable ECGKestra Medical Technologies provides clear evidence of robust support, including a dedicated helpline for service, patient service representatives for fitting and training, and comprehensive patient handbooks and user manuals. This level of documented support is crucial for a wearable medical device. Tool B's information on support and documentation is limited to general instructions for integration.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | ASSURE Wearable ECG | prolaio eVO2peak Module |
|---|---|---|
| Name | ASSURE Wearable ECG | prolaio eVO2peak Module |
| Company | Kestra Medical Technologies | Prolaio |
| Primary Function | Non-therapeutic device for continuous heart rate monitoring and data collection, integrated into a digital healthcare platform for at-risk cardiac patients. | FDA-cleared software to estimate peak oxygen consumption using real-world patient data for cardiovascular research and care. |
| Core Technology/Inputs | Wearable ECG device, SensorFit Garment with non-adhesive, embedded, and cushioned ECG sensors, ASSURE Detection Algorithm with Quad Channel Processingu2122, Adaptive Patient Intelligenceu2122 for filtering motion artifacts. | Utilizes demographic data, single-lead ECG, and triaxial accelerometry inputs; processes data from qualified third-party FDA-cleared wearable medical sensors; applies a locked deep-learning model. |
| Key Output/Purpose | Continuous heart rate monitoring, automatic episode storage, alert-based notifications, physiologic trend data, remote patient data platform for clinician review. | Estimates peak oxygen consumption (eVO2peak), provides information as an adjunctive aid in clinical evaluation, enables high-density, longitudinal data collection. |
Videos
Demos, reviews, and walkthroughs featuring ASSURE Wearable ECG and prolaio eVO2peak Module.